The WHO Collaborating Centre for Research and Training in Management of MDR-TB (WHO CC), of Centre of Tuberculosis and Lung Diseases, Riga East University hospital for more than 15 years provides high quality, evidence-based health care personnel capacity development activities in line with worldwide evidence, latest scientific developments, WHO guidance, as well as regional policy frameworks in practical aspects of the treatment and management of drug-resistant tuberculosis (DR-TB).

WHO CC Latvia offers and runs more than 20 comprehensive training programs for TB specialists, paediatricians, laboratory staff, surgeons, public health and TB control program representatives. Training curriculum is constantly adopted according to rapidly changing international evidence and WHO policies on the diagnosis, treatment and management of DR-TB. Faculty of WHO CC Latvia involves more than 20 experts, clinicians and scientists; internationally recognized experts from other countries are regularly involved in the training activities.

Over the years WHO CC Latvia has facilitated different courses, workshops and exchange of experience activities. Since 2001 nearly 3000 participants from more than 60 countries have attended the WHO CC Latvia training activities.

Training activities are delivered in different formats - workshops, hands-on training, intensive courses, conferences, scientific symposiums and using a variety of methods – lectures, case studies, group discussions, practical visits to sites, online presentations, etc.

Duration for intensive courses varies from 5 to 9 working days.

Training courses are offered in the Russian and English languages.

Training facilities and sites: Location of WHO CC Latvia is the Tuberculosis and Lung Disease Centre of Riga East University where most of the training courses are held, therefore an important part of the training programmes are practical visits to see the work of the Multidrug resistant TB ward, TB laboratory, Out-patient department as well as introduce with the infection control measures, nursing process, patient management and collaboration among services in Latvia to ensure people-centred TB care.
**WHO Collaborating Centre for Research and Training in Management of Multidrug-Resistant Tuberculosis, Latvia**

## TRAINING ANNOUNCEMENT 2020

<table>
<thead>
<tr>
<th>TIME</th>
<th>COURSE AND DURATION</th>
<th>LANGUAGE</th>
<th>REGISTRATION DEADLINE</th>
</tr>
</thead>
<tbody>
<tr>
<td>02/03 - 11/03</td>
<td>Programmatic and clinical management of drug-resistant tuberculosis in order to achieve sustainable development goals, 9 working days</td>
<td>RUSSIAN</td>
<td>03/02/2020</td>
</tr>
<tr>
<td>29/06 - 08/07</td>
<td>Programmatic and clinical management of drug-resistant tuberculosis in order to achieve sustainable development goals, 9 working days</td>
<td>ENGLISH</td>
<td>25/05/2020</td>
</tr>
<tr>
<td>24/08 - 02/09</td>
<td>Programmatic and clinical management of drug-resistant tuberculosis in order to achieve sustainable development goals, 9 working days</td>
<td>RUSSIAN</td>
<td>17/06/2020</td>
</tr>
<tr>
<td>21/09 - 25/09</td>
<td>New! Strengthening the capacity of nurse in effective, comprehensive, integrated people-centred TB care, 5 working days</td>
<td>RUSSIAN</td>
<td>03/08/2020</td>
</tr>
<tr>
<td>12/10 - 16/10</td>
<td>Tuberculosis laboratory aid in the people-centered diagnosis and management of tuberculosis, 5 working days</td>
<td>RUSSIAN</td>
<td>07/08/2020</td>
</tr>
<tr>
<td>09/11 - 13/11</td>
<td>Programmatic introduction of the new and repurposed anti-tuberculosis medicines for treatment of drug-resistant tuberculosis, 5 working days</td>
<td>RUSSIAN</td>
<td>11/09/2020</td>
</tr>
<tr>
<td>20/11 - 21/11</td>
<td>4th Baltic States Symposium: Progress in achieving end TB milestones for 2020 and the way forward to sustainable development goals in Baltics, 1.5 working days</td>
<td>ENGLISH</td>
<td>With invitations</td>
</tr>
</tbody>
</table>

Upon request, different types of in-country trainings/workshops/consultations are offered, including drug resistant tuberculosis and new drugs management, childhood TB, effective health communication and training of trainers.

www.tblatvia.com

**COURSE DIRECTOR:** Dr. Liga Kuksa, liga.kuksa@aslimnica.lv

**COURSE COORDINATORS:** Ms. Liga Rusmane, Ms. Ita Sprukule, mdr.tb.training@aslimnica.lv
Programmatic and clinical management of drug-resistant tuberculosis in order to achieve sustainable development goals

COURSE MODULES:

- Global epidemiology of TB, DR-TB, TB/HIV and WHO strategy and targets for TB prevention, care, and control.
- Updates on diagnosis of TB and DR-TB and TB diagnostic algorithm proposed by the European TB Laboratory Initiative.
- Clinical aspects of case detection of DR-TB.
- Use of shorter DR-TB regimens in European regions. New guidelines for treatment of RR-TB. Treatment regimen design for DR-TB.
- TB diagnosis and treatment for HIV co-infected patients. Possible drug-drug interactions between antiretrovirals and the new TB drugs.
- Diagnosis and treatment of latent TB infection.
- Monitoring of DR-TB treatment effectiveness.
- Pharmacovigilance. Active drug safety monitoring and management (aDSM).
- Fundamentals of infection control; FAST: a TB infection control strategy.
- Contact finding and investigation.
- Organisation of TB ambulatory treatment. DR-TB case management ambulatory, including patient adherence and collaboration with local NGO’s, social and other healthcare services.
- Developing models of care for DR-TB patients; people-centered TB care.
- Health communication for health care workers working with TB.
- Management of failures and chronic patients.
- Intersectoral collaboration on ending TB, HIV and Hepatitis C in countries.

TARGET AUDIENCE:
Clinicians, staff of national TB programs, persons responsible for diagnostics and treatment of DR-TB, from countries with high levels of DR-TB

LANGUAGE:
Russian/English

DURATION:
9 business days (from Monday to Wednesday, including Saturday)

TRAINING FEE:
1700 EUR, including training materials, site visit, local transport, catering during working hours/on working days, visa invitation support.

Additional costs: hotel accommodation (from ~ 40 EUR to ~ 80 EUR per night), international flight, visa, reduced daily allowance.
Programmatic introduction of the new and re-purposed anti-tuberculosis medicines for treatment of drug-resistant tuberculosis

COURSE MODULES:
- Global epidemiology of TB, DR-TB, and TB/HIV; WHO strategy and targets for TB prevention, care and control.
- Perspectives of the National Tuberculosis Programs on implementing innovative diagnostics and treatment for DR-TB.
- Laboratory diagnosis of TB and TB drug resistance; TB diagnostic algorithm proposed by the European TB Laboratory Initiative (ELI).
- Programmatic approach to the treatment of rifampicin-resistant TB (RR-TB); the role of clinicians in the introduction of new and repurposed drugs and regimens for different types of resistance.
- Clinical issues in new drug introduction, regimen design, and drug-drug interactions; off-label use of new TB drugs; use in special populations.
- Role of patient-centred care, support and adherence-support package; ethical considerations and informed consent.
- Adjuvant therapies; the role of surgery using new and re-purposed drugs.
- Drug safety; scope of safety data collection and definitions; active drug safety monitoring and management (aDSM).
- Clinical management of adverse events of interest: peripheral neuropathy, myelosuppression, prolonged QT interval, optic nerve disorder (optic neuritis), hepatitis, acute kidney injury, hearing impairment, hypokalemia, and hypothyroidism.
- Monitoring and evaluation requirements for the use of new and re-purposed drugs; length of therapy with new drugs.
- Pharmacokinetic and minimum inhibitory concentration (MIC) variability as determinants of TB clinical outcomes in adults and children - state of the evidence.

TARGET AUDIENCE:
Clinicians, staff of national TB programs, persons responsible for diagnostics and treatment of DR-TB, from countries with high levels of DR-TB.

TRAINING FEE:
1200 EUR, including training materials, site visit, local transport, catering during working hours/on working days, visa invitation support.

DURATION:
5 business days (from Monday to Friday).

LANGUAGE: Russian

Additional costs: hotel accommodation (from ~ 40 EUR to ~ 80 EUR per night), international flight, visa, reduced daily allowance.
This hands-on work training was designed by combining the latest evidence and recommendations on rapid molecular diagnostic methods with practical work at the TB Supranational Reference Laboratory in Riga, Latvia.

COURSE MODULES:

- Epidemiology of TB, DR-TB and TB/HIV.
- Updates on diagnosis of TB and TB drug resistance. Proposed TB diagnostic algorithm by the European TB Laboratory Initiative (ELI).
- Use of shorter DR-TB regimens in European regions.
- TB Laboratory services and laboratory network, possibilities of integration with HIV, Viral hepatitis programs.
- Detection of mutations associated with resistance anti-TB medicines.
- Mowing towards laboratory accreditation, internal and external quality control.
- Infection control requirement for laboratories at different levels.
- Drug susceptibility testing for new and repurposed anti-TB medicines.
- Laboratory detection of latent TB infection for strengthening preventive treatment of contacts and high risk groups.
- Effective communication for ensuring precise reporting and interpretation of the results.

TARGET AUDIENCE:
TB Laboratory specialists

DURATION:
5 business days (from Monday to Friday)

LANGUAGE:
Russian

TRAINING FEE:
1280 EUR, including training materials, site visit, local transport, catering during working hours/on working days, visa invitation support.

Additional costs: hotel accommodation (from ~ 40 EUR to ~ 80 EUR per night), international flight, visa, reduced daily allowance.
New! Strengthening the capacity of nurse in effective, comprehensive, integrated people-centred tuberculosis care

This course is designed to empower and strengthen capacity of nurses and public health staff working in TB care settings for universal coverage of people-centred TB care. Objectives of this course are to scale-up approaches and introduce with best practices in people-oriented model of TB care for better diagnosis and treatment outcomes.

COURSE MODULES:

- Global epidemiology of TB, DR-TB, TB/HIV and WHO strategy and targets for TB prevention, care, and control.
- WHO evidence and policy framework on people-centred TB care.
- Nursing approach to a people-centred model of TB care.
- Latest updated and evidence in TB clinical management.
- Professional competences of nurses in TB field.
- TB nursing care in improved prevention, detection and treatment of TB.
- Digital health solutions for treatment adherence and patient support.
- VOT as treatment adherence intervention.
- Effective healthcare communication.
- Education and counselling in TB care.
- TB patient care in inpatient and outpatient settings.
- Role of intersectoral collaboration in effective TB care.
- Fundamentals of infection control.

TARGET AUDIENCE:
TB nurses, other public health staff involved in TB care

DURATION:
5 business days (from Monday to Friday)

LANGUAGE:
Russian

TRAINING FEE:
1200 EUR, including training materials, site visit, local transport, catering during working hours/on working days, visa invitation support

Additional costs: hotel accommodation (from ~ 40 EUR to ~ 80 EUR per night), international flight, visa, reduced daily allowance.